Effect of acetazolamide and furosemide in combination for acute heart failure with volume overload under sodium glucose co-transportor 2 inhibitor

Effect of acetazolamide and furosemide in combination for acute heart failure with volume overload under sodium glucose co-transportor 2 inhibitor - Combination therapy with acetazolamide and furosemide for acute heart failure

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031230483

Enrollment

Registered

2023-11-29

Start date

2023-11-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute heart failure

Interventions

A patient who meets inclusion criteria, and has provided written informed consent to participate in this study, will be randomly assigned into 2 groups as shown below. [treatment group (Acetazolamide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) A patient aged 18 years or older at the time of enrollment. 2) A patient hospitalized for acute heart faiure based on Framingham criteria. 3) NT-proBNP > 1000pg/mL or BNP > 250pg/mL 4) A patient who has clinical sign of volume overload. (edema, pleural effusion, ascites or juglar vein retension). 5) A patients who have taken sodium glucose co-transportor 2 inhibitors (dapagliflozin or empagliflozin) for at least 1 month. 6) A patient who has provided written informed consent to participate in this study (if the patient can not sign by oneself, it is acceptable that a family or a person following a family writes on behalf).

Exclusion criteria

Exclusion criteria: 1) Receipt of acetazolamide maintenance therapy or intolerance for acetazolamide 2) Type 1 diabetes 3) Symptomatic hypotension 4) A Patient expected to receive intravenous inotropes 5) A history of acute coronary syndrome, stroke or transient ischemic attack within 3 months before screening. 6) A history of allergy for sodium glucose co-transportor 2 inhibitor or acetazolamide 7) Restrictive cardiomyopathy, active myocarditis or hypertrophic obstructive cardiomyopathy 8) Na >145 mEq/L, Na 3.5mg/dL, eGFR < 20mL/min/1.73m2) 11) Anurea or hypourea (daily urine output < 400mL) 12) Renal replacement therapy 13) Pregnant, possibly pregnant, within 28 days postpartum or nursing women 14) A patient whom the investigator considers to be ineligible as a subject

Design outcomes

Primary

Measure	Time frame
Cumulative natriuresis for three days	—

Secondary

Measure	Time frame
[Efficacy] Body weight Urine volume NT-proBNP Visual analogue scale Length of hospitalization [Safety] adverse events	—

Contacts

Public ContactHirotoshi Kato

Chiba University Hospital

ayma4436@chiba-u.jp+81-432227171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026